Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers

Abstract

The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.

1 - 97 . (canceled) 
     
     
         98 . A method for treating a human patient for a cancer situated in a lung tissue, the method comprising:
 administering to the patient a medicament comprising an effective amount of an antigenic composition comprising antigenic determinants characteristic of  Klebsiella pneumoniae , the antigenic determinants together being specific for  Klebsiella pneumoniae  so that the composition elicits an immune response in the patient that is specific for  Klebsiella pneumoniae.      
     
     
         99 . The method according to  claim 98 , wherein the method comprises administering the medicament in successive doses given at a dosage interval of between one hour and one month, over a dosage duration of at least two weeks. 
     
     
         100 . The method according to  claim 99 , wherein the method comprises administering the medicament in a dose so that each dose is effective to cause a localized inflammatory immune response at an administration site. 
     
     
         101 . The method according to  claim 100 , wherein the administration site is distant from the lung. 
     
     
         102 . The method of  claim 101 , wherein the method comprises administering the medicament in a manner such that visible localized inflammation at the administration site occurs within 1 to 48 hours. 
     
     
         103 . The method according to  claim 98 , wherein the method comprises administering the medicament intradermally or subcutaneously. 
     
     
         104 . The method according to  claim 102 , wherein the method comprises administering the medicament intradermally or subcutaneously. 
     
     
         105 . The method according to  claim 98 , wherein the method comprises intranasal, inhalational, or aerosol, administration of the medicament. 
     
     
         106 . The method according to  claim 99 , wherein the method comprises intranasal, inhalational, or aerosol, administration of the medicament. 
     
     
         107 . The method according to  claim 98 , wherein the method further comprises administering to the patient an effective amount of cisplatin. 
     
     
         108 . The method according to  claim 99 , wherein the method further comprises administering to the patient an effective amount of cisplatin. 
     
     
         109 . The method according to  claim 104 , wherein the method further comprises administering to the patient an effective amount of cisplatin. 
     
     
         110 . The method according to  claim 106 , wherein the method further comprises administering to the patient an effective amount of cisplatin. 
     
     
         111 . The method of  claim 98 , wherein the patient is a patient that has been diagnosed as having suffered from a prior pathogenic exposure to  Klebsiella pneumoniae.    
     
     
         112 . The method according to  claim 98 , wherein the medicament is administered to the subject in an amount and for a time that is effective to modulate an immune response. 
     
     
         113 . The method of  claim 112 , wherein the modulation of the immune response comprises a shift in the activation state of macrophages. 
     
     
         114 . The method of  claim 113 , wherein the modulation of the immune response comprises shifting from a M2-like macrophage response to a M1-like macrophage response. 
     
     
         115 . The method of  claim 112 , wherein the method further comprises measuring a characteristic of the immune response. 
     
     
         116 . The method of  claim 115 , wherein measuring the characteristic of the immune response comprises comparing an indication of the numbers of any one or more of the following cells: inflammatory monocytes, macrophages, CD11b +  Gr-1 +  cells, dendritic cells, CD11c +  MHC class II +  cells, CD4 +  T cells, CD8 +  T cells, or NK cells. 
     
     
         117 . A method for treating a human patient for a cancer situated in a lung tissue, the method comprising:
 administering to the patient a medicament comprising an effective amount of an antigenic composition comprising antigenic determinants characteristic of  Klebsiella pneumoniae , the antigenic determinants together being specific for  Klebsiella pneumoniae  so that the composition elicits an immune response in the patient that is specific for  Klebsiella pneumoniae;      administering the medicament in successive doses given at a dosage interval of between one hour and one month, over a dosage duration of at least two weeks in an amount and for a time that is effective to modulate an immune response, and the modulation of the immune response comprises a shift in the activation state of macrophages from a M2-like macrophage response to a M1-like macrophage response; and,   administering to the patient an effective amount of cisplatin.